IL90529A - Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma - Google Patents

Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma

Info

Publication number
IL90529A
IL90529A IL9052989A IL9052989A IL90529A IL 90529 A IL90529 A IL 90529A IL 9052989 A IL9052989 A IL 9052989A IL 9052989 A IL9052989 A IL 9052989A IL 90529 A IL90529 A IL 90529A
Authority
IL
Israel
Prior art keywords
composition
antibody
administration
leukocytes
inflammation
Prior art date
Application number
IL9052989A
Other languages
English (en)
Other versions
IL90529A0 (en
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of IL90529A0 publication Critical patent/IL90529A0/xx
Publication of IL90529A publication Critical patent/IL90529A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL9052989A 1988-06-07 1989-06-05 Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma IL90529A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20403788A 1988-06-07 1988-06-07
US07/331,450 US5147637A (en) 1988-06-07 1989-03-31 Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma

Publications (2)

Publication Number Publication Date
IL90529A0 IL90529A0 (en) 1990-01-18
IL90529A true IL90529A (en) 1994-01-25

Family

ID=26899117

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9052989A IL90529A (en) 1988-06-07 1989-06-05 Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma

Country Status (10)

Country Link
US (1) US5147637A (fr)
EP (1) EP0346078A3 (fr)
JP (1) JPH02104534A (fr)
KR (1) KR910000184A (fr)
AU (1) AU620100B2 (fr)
DK (1) DK278589A (fr)
FI (1) FI892793A7 (fr)
IL (1) IL90529A (fr)
NO (1) NO892319L (fr)
PT (1) PT90775B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432249B1 (fr) 1989-06-02 1996-09-25 The Johns Hopkins University School Of Medicine Anticorps monoclonaux contre la chaine beta de recepteurs d'adhesion de leucocytes, procede de production de ces anticorps et utilisation
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
JPH06500555A (ja) * 1990-08-27 1994-01-20 カイロン　コーポレイション 病気の処置のためのペプチドの薬物
WO1992004034A1 (fr) * 1990-08-31 1992-03-19 Boehringer Ingelheim Pharmaceuticals, Inc. Procede traitant les chocs endotoxiniques au moyen d'anticorps anti-adhesion
EP0565642A1 (fr) * 1991-01-11 1993-10-20 Repligen Corporation Procede de prevention des lesions inflammatoires
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
ATE145827T1 (de) * 1991-04-03 1996-12-15 Boehringer Ingelheim Pharma Verfahren zur hemmung der sauerstofftoxizität in den lungen
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
CA2119128C (fr) * 1992-07-16 2000-05-30 Lynn M. Rose Soulagement des symptomes associes aux etats inflammatoires aigus
CA2140933A1 (fr) * 1992-08-21 1994-02-22 Paula M. Jardieu Methode de traitement pour les atteintes dues a la molecule lfa-1
WO1994012214A1 (fr) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Anticorps humanises reagissant avec la cd-18
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000056363A1 (fr) 1999-03-19 2000-09-28 Genentech, Inc. Traitement de troubles associes au lfa-1 par augmentation des doses d'antagoniste de lfa-1
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
WO2001002009A1 (fr) * 1999-07-06 2001-01-11 Johns Hopkins University Methode d'inhibition de l'angiospasme et composition a cet effet
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
JP2004507448A (ja) * 2000-03-18 2004-03-11 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 狭窄症関連疾患を抑制するｃｄ−１８結合抗体
EP1756163A2 (fr) 2004-06-09 2007-02-28 Genentech, Inc. Procede de traitement du granulome annulaire ou sarcoide
WO2008101133A2 (fr) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Procédés d'utilisation de gènes et de variants génétiques pour prévoir ou diagnostiquer une affection abdominale inflammatoire
CA3204588A1 (fr) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methodes de diagnostic et de traitement de la maladie de crohn
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (fr) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Procédés d’utilisation de gènes de la voie il17rd et il23-il17 pour diagnostiquer la maladie de crohn
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (fr) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Méthodes de prédiction de colite ulcéreuse réfractaire aux traitements (mr-uc) nécessitant une colectomie
ES2705244T3 (es) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común
EP2968309A4 (fr) 2013-03-13 2016-08-31 Inflammatory Response Res Inc Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2021236518A1 (fr) 2020-05-19 2021-11-25 IRR, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
WO1988006592A1 (fr) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Clonage de lfa-1
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy

Also Published As

Publication number Publication date
JPH02104534A (ja) 1990-04-17
FI892793L (fi) 1989-12-08
AU3608489A (en) 1989-12-14
AU620100B2 (en) 1992-02-13
US5147637A (en) 1992-09-15
DK278589A (da) 1989-12-08
FI892793A0 (fi) 1989-06-07
FI892793A7 (fi) 1989-12-08
NO892319L (no) 1989-12-08
EP0346078A3 (fr) 1991-03-20
IL90529A0 (en) 1990-01-18
NO892319D0 (no) 1989-06-06
PT90775B (pt) 1994-11-30
PT90775A (pt) 1989-12-29
KR910000184A (ko) 1991-01-29
DK278589D0 (da) 1989-06-07
EP0346078A2 (fr) 1989-12-13

Similar Documents

Publication Publication Date Title
US5147637A (en) Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
Odenholt Pharmacodynamic effects of subinhibitory antibiotic concentrations
Dominioni et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater
Clissold et al. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
Stegmayr et al. Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects
CA2769394C (fr) Anticorps monoclonal humain contre l'alpha-toxine derivee de s. aureus et son utilisation dans le traitement ou la prevention de la formation d'abces
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
Rolston et al. Pseudomonas aeruginosa infection in cancer patients: Infectious complications of cancer
US5322699A (en) Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
Gnann Jr et al. Ceftriaxone: in vitro studies and clinical evaluation
Bayer et al. Valve site-specific pathogenetic differences between right-sided and left-sided bacterial endocarditis
Morse et al. Once weekly intraperitoneal therapy for gram-positive peritonitis
Täuber et al. General principles of therapy of pyogenic meningitis
WO2003041726A1 (fr) Utilisation d'une proteine d'adherence extracellulaire pour la fabrication d'un anti-inflammatoire
Moore et al. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa
NZ229434A (en) Anti-cd18 antibodies, their use and compositions thereof for inhibiting leukocyte influx
US6315999B1 (en) Pharmaceutical product for the treatment of sepsis
Jenkinson et al. Cefotaxime in the treatment of pneumococcal pneumonia
EP0486609A1 (fr) Produit pharmaceutique de traitement de la septicemie.
Stephens ICU complications of hematopoietic stem cell transplant, including graft vs host disease
CA2100084A1 (fr) Methode de prevention des lesions inflammatoires
Woodnutt et al. Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum
EP0584273B1 (fr) Anticorps reconnaissant le ligand de cellules endotheliales du leucocyte cr3
AU6122894A (en) Method for modulating transendothelial migration of cells promoting inflammation, and related methods of measurement thereof
Majcherczyk et al. Isolation and in-vitro and in-vivo characterisation of a mutant of Pseudomonas aeruginosa PAO1 that exhibited a reduced postantibiotic effect in response to imipenem

Legal Events

Date Code Title Description
RH Patent void